Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development
The aim of the present work was to develop immediate release dosage form of the solid dispersion of glimperide (GLIM) for potential enhancement in the bioavailability. The solid dispersions of GLIM were prepared with PEG6000, PVP K30 and Poloxamer 188, in 1:1, 1:3 and 1:5 %w/w ratio by using solvent...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Mazandaran University of Medical Sciences
2017-12-01
|
Series: | Pharmaceutical and Biomedical Research |
Subjects: | |
Online Access: | http://pbr.mazums.ac.ir/article-1-181-en.pdf |
id |
doaj-f9e7eebe730c4534af007f74c5ef2811 |
---|---|
record_format |
Article |
spelling |
doaj-f9e7eebe730c4534af007f74c5ef28112020-11-25T00:55:11ZengMazandaran University of Medical SciencesPharmaceutical and Biomedical Research2423-44942423-44942017-12-013411310.18502/pbr.v3i4.84Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form developmentKamla Pathak0Suchitra Kaushik1Pharmacy College Saifai, Uttar Pradesh University of Medical Sciences, Etawah, 206130, INDIAPharmacy College Saifai, Uttar Pradesh University of Medical Sciences, Etawah, 206130, INDIAThe aim of the present work was to develop immediate release dosage form of the solid dispersion of glimperide (GLIM) for potential enhancement in the bioavailability. The solid dispersions of GLIM were prepared with PEG6000, PVP K30 and Poloxamer 188, in 1:1, 1:3 and 1:5 %w/w ratio by using solvent wetting and solvent melt method. The in vitro dissolution parameters (%DE10min, %DE30min, %DE60min, T50% and DP30) were used to select the optimized solid dispersion that was characterized by IR, PXRD, DSC and SEM. The optimized solid dispersion of GLIM (GSDSM3) was used as drug component for immediate release (IR) tablets that were evaluated for physical and pharmacopoeial parameters. The in vitro drug release studies identified G4 as the optimized tablet with a cumulative drug release (CDR) of 99.34% in 30 min in phosphate buffer, pH 7.4. The CDR was higher than the marketed tablet (91.15%, Amaryl®, Sanofiaventis), However, the f1 and f2 were 10.6 and 52 respectively, which confirmed similarity of the dissolution profile(s). Accelerated stability studies confirmed stability up to 6 months at 40°C/75% condition in the HDPE bottle pack.http://pbr.mazums.ac.ir/article-1-181-en.pdfGlimperidesolid dispersionsolvent wetting methodsolvent melt methodimmediate release tablet |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Kamla Pathak Suchitra Kaushik |
spellingShingle |
Kamla Pathak Suchitra Kaushik Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development Pharmaceutical and Biomedical Research Glimperide solid dispersion solvent wetting method solvent melt method immediate release tablet |
author_facet |
Kamla Pathak Suchitra Kaushik |
author_sort |
Kamla Pathak |
title |
Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development |
title_short |
Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development |
title_full |
Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development |
title_fullStr |
Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development |
title_full_unstemmed |
Solubility enhancement of glimperide: Development of solid dispersion by solvent melt method, characterization and dosage form development |
title_sort |
solubility enhancement of glimperide: development of solid dispersion by solvent melt method, characterization and dosage form development |
publisher |
Mazandaran University of Medical Sciences |
series |
Pharmaceutical and Biomedical Research |
issn |
2423-4494 2423-4494 |
publishDate |
2017-12-01 |
description |
The aim of the present work was to develop immediate release dosage form of the solid dispersion of glimperide (GLIM) for potential enhancement in the bioavailability. The solid dispersions of GLIM were prepared with PEG6000, PVP K30 and Poloxamer 188, in 1:1, 1:3 and 1:5 %w/w ratio by using solvent wetting and solvent melt method. The in vitro dissolution parameters (%DE10min, %DE30min, %DE60min, T50% and DP30) were used to select the optimized solid dispersion that was characterized by IR, PXRD, DSC and SEM. The optimized solid dispersion of GLIM (GSDSM3) was used as drug component for immediate release (IR) tablets that were evaluated for physical and pharmacopoeial parameters. The in vitro drug release studies identified G4 as the optimized tablet with a cumulative drug release (CDR) of 99.34% in 30 min in phosphate buffer, pH 7.4. The CDR was higher than the marketed tablet (91.15%, Amaryl®, Sanofiaventis), However, the f1 and f2 were 10.6 and 52 respectively, which confirmed similarity of the dissolution profile(s). Accelerated stability studies confirmed stability up to 6 months at 40°C/75% condition in the HDPE bottle pack. |
topic |
Glimperide solid dispersion solvent wetting method solvent melt method immediate release tablet |
url |
http://pbr.mazums.ac.ir/article-1-181-en.pdf |
work_keys_str_mv |
AT kamlapathak solubilityenhancementofglimperidedevelopmentofsoliddispersionbysolventmeltmethodcharacterizationanddosageformdevelopment AT suchitrakaushik solubilityenhancementofglimperidedevelopmentofsoliddispersionbysolventmeltmethodcharacterizationanddosageformdevelopment |
_version_ |
1725231547788820480 |